Article
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients.
Oncoimmunology - 1 Jan 2023
García-Mulero Sandra, Fornelino Roberto, Punta Marco, Lise Stefano, Varela Mar, Del Carpio Luis P, Moreno Rafael, Costa-García Marcel, Rieder Dietmar, Trajanoski Zlatko, Gros Alena, Alemany Ramón, Piulats Josep María, Sanz-Pamplona Rebeca
Abstract excerpt
Uveal melanoma (UM) is the most common ocular malignancy in adults. Nearly 95% of UM patients carry the mutually exclusive mutations in the homologous genes GNAQ (amino acid change Q209L/Q209P) and GNA11 (aminoacid change Q209L). UM is located in an immunosuppressed organ and does not suffer immunoediting. Therefore, we hypothesize that driver mutations in GNAQ/11 genes could be recognized by the immune system....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.